JTCC Approved As Member of Georgetown Lombardi Comprehensive Cancer Center Consortium
What You Need To Know
The National Cancer Institute (NCI) has approved John Theurer Cancer Center at Hackensack as a research consortium member of the NCI-approved Georgetown Lombardi Comprehensive Cancer Center Consortium.
Only 16 cancer consortia are recognized by the NCI.
About the Georgetown Lombardi Comprehensive Cancer Center Consortium
The Georgetown Lombardi Comprehensive Cancer Center Consortium advances research and innovates treatment in four key areas: Breast Cancer, Cancer Prevention and Control, Experimental Therapeutics and Molecular Oncology.
John Theurer Cancer Center has worked with the Georgetown Lombardi Comprehensive Cancer Center since 2013. The consortium serves patients in the New York, New Jersey and Washington, D.C. metro areas. The Consortium’s strategic objectives are to:
- advance transformative cancer research
- reduce the impact of cancer and diminish disparities in our catchment area
- lead high-impact clinical research
- ensure long-term growth, vibrancy and stability of the research enterprise
- develop the next generation of cancer scientists, clinicians and educators.
John Theurer Cancer Center supports one of the largest bone marrow transplant (BMT) programs in the Northeast, performing well over 400 transplants annually.
In 2014, John Theurer established a BMT program at Georgetown Lombardi, expanding access to this life-saving treatment in the Washington, DC area.
Together, the two centers have also expanded the ability to bring CAR T-cell therapy, a revolutionary customized immunotherapy, to more people and invest in studies to assess other potential uses of this immunotherapy.
John Theurer’s multiple myeloma program brings a new expertise to Georgetown Lombardi and to their patients who can benefit from advances in treatment.